Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models

Journal of Hypertension

Volumn 28, Issue 8, 2010, Pages 1666-1675

  Sharkovska, Yuliya ^a,b   Kalk, Philipp ^b,c   Lawrenz, Bettina ^d   Godes, Michael ^b   Hoffmann, Linda Sarah ^d,e   Wellkisch, Kathrin ^b   Geschka, Sandra ^d   Relle, Katharina ^a,b   Hocher, Berthold ^a,b   Stasch, Johannes Peter ^d,e  

^a UNIVERSITY OF POTSDAM   (Germany)

^b VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d BAYER PHARMA AG   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

BAY 63 2521; hypertension; nitric oxide; renin; riociguat; soluble guanylyl cyclase

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BAY 63 2521; CREATININE; GUANYLATE CYCLASE; N(G) NITROARGININE METHYL ESTER; RENIN; RIOCIGUAT; UNCLASSIFIED DRUG; UREA; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; EXPERIMENTAL STUDY; GLOMERULOSCLEROSIS; HEART INJURY; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HYPERTENSION; IN VITRO STUDY; LOW DRUG DOSE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; UREA BLOOD LEVEL;

EID: 77954954721     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833b558c     Document Type: Article

References (31)

1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121:1244-1263.
2. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5:755-768.
3. Schermuly RT, Stasch JP, Pullamsetti SS, Middendorff R, Müller D, Schlü ter KD, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32:881-891.
4. Frey R, Mück W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008; 48:926-934.
5. KalkP, Godes M, Relle K,RothkegelC,Hucke A, Stasch JP, HocherB.NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol 2006; 148:853-859.
6. Hirth-Dietrich C, Stasch JP, Ganten D. Transgenic rats with an additional renin gene (TGR(mRen2)27) as a sensitive model for the renal effects of NO Synthase inhibition. Naunyn-Schmiedeberg's Arch Pharmacol 1994; 350:R6.
7. Navarro-Cid J, Rosaura M, Rodrigo E, Munos-Garcia R, Ruilope LM, Lahera V, Cachofeiro V. Renal and vascular consequences of the chronic nitric oxide synthase inhibition. Effects of antihypertensive drugs. Am J Hypertens 1996; 9:1077-1083.
8. Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M, et al. Discovery of riociguat (BAY 63-2521): a potent, orally active stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Chem Med Chem 2009; 4:853-865.
9. Mülsch A, Oelze M, Kloss S, Mollnau H, Topfer A, Smolenski A, et al. Effects of in vivo nitroglycerine treatment on activity and expression of guanylyl cyclase and cGMP-dependent protein kinase and their down-stream target vasodilator-stimulated phosphoprotein in aorta. Circulation 2001; 103:2188-2194.
10. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, et al. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br JPharmacol 2002; 135:333-343. (Pubitemid 34151165)
11. Ando Y, Minami H, Saka H, Ando M, Sakai S, Shimokata K. Adjustment of creatinine clearance improve accuracy of Calvert's formula for carboplatin dosing. Br J Cancer 1997; 67:1967-1971.
12. Haffner D, Hocher B, Muller D, Simon K, Konig K, Richter CM, et al. Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 2005; 23:1067-1075.
13. Dumitrascu R,WeissmannN,Ghofrani HA, BeuerleinK,Schmidt H,Stasch JP, et al. Activation of soluble guanylate cyclase reverses lung vascular remodelling and pulmonary hypertension evoked by hypoxia in mice. Circulation 2006; 113:286-295.
14. Zanfolin M, Faro R, Araujo EG, Guaraldo AM, Antunes E, De Nucci G. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J Cardiovasc Pharmacol 2006; 47:391-395.
15. Hocher B, George I, Diekmann F, Zart R, Rebstock J, Schwarz A, et al. ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats. J Hypertens 2000; 18:1807-1814.
16. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. In: Hofmann F, Schmidt HHHW, Stasch JP, editors. cGMP generators, effectors and therapeutic implications. Vol.191: Handbook of experimental pharmacology. Berlin: Springer-Verlag; 2008. pp. 277-308.
17. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bölkow D, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33:717-721.
18. Ghofrani HA, Hoeper MM, HoeffkenG,Halank M, Weimann G,Grimminger F. Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH). BMC Pharmacol 2009; 9 (Suppl 1):S14.
19. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Int Med 1991; 114:667-677.
20. Münzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 1996; 98:1465-1470.
21. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001; 410:212-215. (Pubitemid 32216593)
22. Wang Y, Krämer S, Loof T, Martini S, Kron S, Kawachi H, et al. Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am J Physiol Renal Physiol 2006; 290:F167-F176.
23. Wang Y, Krämer S, Loof T, Martini S, Kron S, Kawachi H, et al. Stimulation of soluble guanylate cyclase slows progression in antithy1-induced chronic glomerulosclerosis. Kidney Int 2005; 68:47-61.
24. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblast. J Clin Invest 1998; 101:812-818.
25. Mori T, Chen YF, Feng JA, Hayashi T, Oparil S, Perry GJ. Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse. Cardiovasc Res 2004; 61:771-779.
26. Silver MA, Maisel A, Yancy CW, Mccullough PA, Burnett JC Jr, Francis GS, etal.BNPConsensusPanel2004:aclinicalapproachforthediagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004; 10:1-30.
27. Takami Y, Horio T, Iwashima Y, Takiuchi S, Kamide K, Yoshihara F, et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in nondialysis-dependent CRF. Am J Kidney Dis 2004; 44:420-428.
28. Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule JC. Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 1999; 99:2185-2191.
29. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000; 97:4239-4244.
30. Rosenkranz AC, Woods RL, Dusting GJ, Ritchie RH. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res 2003; 57:515-522.
31. Masuyama H, Tsuruda T, Sekita Y, Hatakeyama K, Imamura T, Kato J, et al. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res 2009; 32:597-603.